Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Afferent Steps Boldly Into Neurotherapeutic Arena With New Shoe Insole

This article was originally published in The Gray Sheet

Executive Summary

Afferent expects to launch a non-invasive shoe insole technology for the palliative treatment of diabetic foot neuropathy in the second half of 2006

You may also be interested in...

Afferent Corp. awarded grant

$750,000 NIH grant will be used to advance neurostimulation device development for stroke patients. The Providence, R.I. firm owns the patents for the technology, which is used to stimulate peripheral structures of the nervous system to alter brain function and restore motor control. Approximately 4.5 mil. Americans suffer from sensory effects due to brain function loss, according to CEO Jason Harry, PhD. The device, consisting of a power generator and surface electrodes, could reach the U.S. market by late 2007. Other possible indications include diabetic peripheral neuropathy and improving sensory function in the elderly...

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.

In A Bizarre Move, Trump Orders GM To Make Ventilators – Even Though The Auto Giant Already Is

President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts